M3R-reactive CD4+ T cell peptide ligands inhibited IFN-γ production in vitro and alleviated salivary gland inflammation in vivo, thus the M3R-reactive CD4+ T cells may become a potential target for the treatment of SS (135). Here, IFNG is linked to synovial sarcoma.